Goyal, A., O’Leary, D., Dabaja, B., Weng, W.-K., Zain, J., Cutler, C., Guitart, J., Kim, Y. H., Geskin, L. J., Hoppe, R. T., Wilson, L. D., Beaven, A. W., Horwitz, S., Allen, P. B., Barta, S. K., Bohjanen, K., Brammer, J. E., Carter, J. B., Comfere, N., … Foss, F. (2024). ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome. Transplantation and Cellular Therapy, 30(11), 1047–1060. https://doi.org/10.1016/j.jtct.2024.08.020

Nikiforow, S., Whangbo, J. S., Reshef, R., Tsai, D. E., Bunin, N., Abu-Arja, R., Mahadeo, K. M., Weng, W.-K., Van Besien, K., Loeb, D., Nasta, S. D., Nemecek, E. R., Zhao, W., Sun, Y., Galderisi, F., Wahlstrom, J., Mehta, A., Gamelin, L., Dinavahi, R., & Prockop, S. (2024). Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol. Blood Advances, 8(12), 3001–3012. https://doi.org/10.1182/bloodadvances.2023011626

Mata, J. R., Zahurak, M., Rosen, N., DeZern, A. E., Jones, R. J., & Ambinder, A. J. (2024). Graft Failure Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Transplantation and Cellular Therapy, 30(6), 588–596. https://doi.org/10.1016/j.jtct.2024.03.018